Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

AGILE (Early Phase Platform Trial for COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04746183
Recruitment Status : Recruiting
First Posted : February 9, 2021
Last Update Posted : August 25, 2021
Sponsor:
Collaborators:
University of Southampton
Liverpool School of Tropical Medicine
Liverpool University Hospitals NHS Foundation Trust
University of Cambridge
Information provided by (Responsible Party):
University of Liverpool

Brief Summary:
The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be determined by the AGILE Scientific Advisory Board based on pre-clinical data, evidence in the clinical setting and GMP capabilities.

Condition or disease Intervention/treatment Phase
Covid19 Drug: CST-2: EIDD-2801 Drug: CST-2: Placebo Drug: Nitazoxanide Drug: VIR-7832 Drug: VIR-7831 Drug: CST-5: Placebo Phase 1 Phase 2

Detailed Description:

AGILE is a multicentre, multi-arm, multi-dose, multi-stage open-label, adaptive, seamless phase I/II Bayesian randomised platform trial to determine the optimal dose, activity and safety of multiple candidate agents for the treatment of COVID-19.

This study allows for the assessment of many candidates at different doses, with the ability to add candidates as they are identified or drop them as their evaluation is completed. Promising candidates will move to the an external trial for further evaluation in the phase II/III setting.

Each candidate will be evaluated in its own trial, randomising between candidate and control with 2:1 allocation in favour of the candidate. Each dose will be assessed for safety sequentially in cohorts of 6 patients. Once a phase II dose has been identified we will assess efficacy by seamlessly expanding into a larger cohort.

AGILE is completely flexible in that the core design in the master protocol (as has been explained above) can be adapted for each candidate based on prior knowledge of the candidate - i.e. population, primary endpoint and sample size can be amended. This will be detailed in each candidate-specific trial protocol of the master protocol.

Candidate-Specific Trial 1 (CST-1): TBC

Candidate-Specific Trial 2 (CST-2): Open-label 2:1 randomised controlled phase I of EIDD-2801 versus standard of care followed by a 1:1 blinded controlled parallel group Phase II trial of EIDD-2801 versus placebo. A phase I will be carried out to confirm the optimal dose in this group. Following a safety review, EIDD-2801 will be tested for efficacy in a blinded placebo controlled randomised phase II trial.

Candidate-Specific Trial 3 (CST-3A): Multicentre, Adaptive, Phase I trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19

Candidate-Specific Trial 3 (CST-3B): A Randomized, Multicentre, Seamless, Adaptive, Phase I/II trial to Determine the optimal dose, Safety and Efficacy of Nitazoxanide for the Treatment of COVID-19

Candidate-Specific Trial 5 (CST-5): Randomized, Multicentre, Seamless, Adaptive, Phase I/II Platform Study to Determine the Phase II dose of VIR-7832, and Evaluate the Safety and Efficacy of VIR-7831 and VIR-7832 for the Treatment of COVID-19

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

CST-2: Open-label 2:1 randomised controlled phase I of EIDD-2801 versus standard of care followed by a 1:1 blinded controlled parallel group Phase II trial of EIDD-2801 versus placebo. A phase I will be carried out to confirm the optimal dose in this group. Following a safety review, EIDD-2801 will be tested for efficacy in a blinded placebo controlled randomised phase II trial.

CST-3A: single arm, open-label phase Ia to confirm the optimum dose, safety and tolerability of Nitazoxanide in healthy volunteers CST-3B: Open-label 1:1 randomised controlled phase Ib of Nitazoxanide versus standard of care (SOC) to confirm the safety and tolerability of Nitazoxanide in participants with COVID-19 followed by a 1:1 blinded parallel group Phase II trial of Nitzaoxanide versus standard of care.

CST-5: 3:1 randomised, blinded, placebo-controlled phase I of VIR-7832, followed by a 2:2:1 blinded, parallel group Phase II trial of VIR-7832 versus VIR-7831 versus placebo.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: CST-2: Phase I, open-label EIDD-2801 vs standard of care. Phase II, blinded controlled parallel group of EIDD-2801 vs placebo CST-3A: Phase Ia, open-label nitazoxanide CST-3B: Phase Ib, II, open label nitazoxanide vs standard of care CST-5: Phase I, blinded VIR-7832 vs placebo, Phase II, blinded VIR-7832 vs VIR-7831 vs placebo
Primary Purpose: Treatment
Official Title: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment
Actual Study Start Date : July 3, 2020
Estimated Primary Completion Date : November 18, 2021
Estimated Study Completion Date : April 30, 2022

Arm Intervention/treatment
Experimental: CST-2 EIDD-2801

EIDD-2801 (also known as MK-4482, molnupiravir). Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.

Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.

Drug: CST-2: EIDD-2801

CST-2 Phase Ib: EIDD-2801 will be administered orally, twice daily (BID) for 10 doses (5 or 6 days). The starting dose will be established based on safety and pharmacokinetics from the EIDD-2801-1001-US/UK study, and dose escalations may occur as described in this CST.

Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.

Other Names:
  • MK-4482
  • Molnupiravir

No Intervention: CST-2 Control
Phase 1b only (standard of care)
Placebo Comparator: CST-2 Placebo
Phase II placebo blinded controlled
Drug: CST-2: Placebo
CST-2 Phase II: Placebo will be administered orally, twice daily (BID) for 10 doses (5 or 6 days).

Experimental: CST-3A Nitazoxanide
Phase Ia Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur
Drug: Nitazoxanide

CST3A & CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.

Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.


Experimental: CST-5 VIR-7832
Single doses of VIR-7832 will be administered by intravenous (IV) infusion. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated.
Drug: VIR-7832

CST-5: Phase I, Single doses of VIR-7832 will be administered by intravenous (IV) infusion over 1 hour. The starting dose will be 50 mg, and dose escalations of 150 and 500 mg are anticipated, with escalation guided by emerging safety data and decision by the SRC.

Phase II: As per Phase I, with the dose determined by the recommended phase II dose.


Active Comparator: CST-5 VIR-7831
Phase II: 500 mg dose of VIR-7831 will be given by IV infusion.
Drug: VIR-7831
CST-5 Phase II: A 500 mg dose of VIR-7831 will also be given by IV infusion over 1 hour.

Placebo Comparator: CST-5 Placebo
Phase I and II placebo blinded controlled
Drug: CST-5: Placebo
CST-5 Phase 1, Phase II: Placebo given by intravenous infusion over 1 hour

Experimental: CST3B Nitazoxanide Drug: Nitazoxanide

CST3A & CST3B Phase I: Nitazoxanide will be administered orally, initially twice daily (BID) for 14 doses (7 days). The starting dose will be 1500mg BID based on existing dose information, but dose adaptations may occur.

Phase II: As per Phase Ib, with the dose determined by the recommended phase II dose.


No Intervention: CST3B Control
Standard of care



Primary Outcome Measures :
  1. Master Protocol: Dose-finding/Phase I [ Time Frame: 29 days from randomisation ]
    Determination of a dose(s) for efficacy evaluation. Dose limiting toxicities (Safety and Tolerability of drug under study - CTCAE v5 Grade ≥3 adverse events)

  2. Master Protocol: Efficacy evaluation/Phase II - Severe patients (Group A) [ Time Frame: 29 days from randomisation ]

    Determination of activity and safety.

    In severe patients (Group A): time to clinical improvement. Improvement will be determined according to the WHO Clinical Progression Scale; improvement is defined as a minimum 2-step change from randomisation in the scale up to day 29 post-randomisation.


  3. Master Protocol: Efficacy evaluation/Phase II - Mild to moderate patients (Group B) [ Time Frame: 15 days from randomisation ]

    Determination of activity and safety.

    In mild to moderate patients (Group B): pharmacodynamics of drug under study, defined as time to negative viral titres in nose and/or throat swab, measured up to 15 days post-randomisation.


  4. CST-2 Phase I: To determine the safety and tolerability of multiple ascending doses of EIDD-2801 to recommend dose for phase II. [ Time Frame: 7 days from randomisation ]

    Dose limiting toxicity (DLT) using CTCAE version 5 (grades 3 and above) over 7 days.

    CTCAE grading related to platelets and/or lymphocytes


  5. CST-2 Phase II: To determine the ability of EIDD-2801 to reduce serious complications of COVID-19 including hospitalization, reduction in SAO2<92%, or death. [ Time Frame: 29 days from randomisation ]
    Progression of disease (SpO2<92% based on at least 2 consecutive recordings on the same day) or hospitalization or death up to day 29


Secondary Outcome Measures :
  1. Master Protocol: Safety assessed by rate of adverse events [ Time Frame: Up to 29 days from randomisation ]
    Adverse event rate according to CTCAE v5

  2. Master Protocol: To evaluate clinical improvement [ Time Frame: From randomisation to day 29 ]
    Proportion of patients with clinical improvement (as defined above) at day 8, 15 and day 29.

  3. Master Protocol: To evaluate clinical improvement using WHO clinical progression scale [ Time Frame: From randomisation to day 15 ]
    Change at day 8 and 15 from randomisation in the WHO Clinical Progression Scale

  4. Master Protocol: To evaluate clinical improvement using WHO clinical progression scale [ Time Frame: From randomisation to day 29 ]
    Time to a one point change on the WHO Clinical Progression Scale

  5. Master Protocol: To evaluate clinical improvement using SpO2/FiO2 [ Time Frame: From randomisation to day 29 ]
    The ratio of the oxygen saturation to fractional inspired oxygen concentration (SpO2/FiO2)

  6. Master Protocol: To evaluate discharge [ Time Frame: From randomisation to day 29 ]
    Proportion of patient discharged at days 8, 15 and 29

  7. Master Protocol: To evaluate admission to ICU [ Time Frame: From randomisation to day 29 ]
    Admission rate to ICU

  8. Master Protocol: To evaluate safety further (WCC) [ Time Frame: From randomisation to day 29 ]
    White cell count on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29

  9. Master Protocol: To evaluate safety further (Hg) [ Time Frame: From randomisation to day 29 ]
    Haemoglobin on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29

  10. Master Protocol: To evaluate safety further (platelets) [ Time Frame: From randomisation to day 29 ]
    Platelets on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29

  11. Master Protocol: To evaluate safety further (creatinine) [ Time Frame: From randomisation to day 29 ]
    Creatinine on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29

  12. Master Protocol: To evaluate safety further (ALT) [ Time Frame: From randomisation to day 29 ]
    ALT on day 1, 3, 5, 8, 11 (while hospitalised); and Day 15 and 29

  13. Master Protocol: To evaluate overall mortality [ Time Frame: From randomisation to day 29 ]
    Mortality at Days 8, 15 and 29. Time to death from randomisation

  14. Master Protocol: To evaluate the number of oxygen-free days [ Time Frame: From randomisation to day 29 ]
    Duration (days) of oxygen use and oxygen-free days

  15. Master Protocol: To evaluate ventilator-free days [ Time Frame: From randomisation to day 29 ]
    Duration (days) of mechanical ventilation and mechanical ventilation-free days

  16. Master Protocol: To evaluate incidence of new mechanical ventilation use [ Time Frame: From randomisation to day 29 ]
    Incidence of new mechanical ventilation use

  17. Master Protocol: To evaluate National Early Warning Score (NEWS)2/qSOFA [ Time Frame: From randomisation to day 29 ]
    NEWS2/qSOFA assessed daily while hospitalised

  18. Master Protocol: To evaluate translational outcomes (Viral Load) [ Time Frame: From randomisation to day 29 ]
    Change in viral load over time

  19. Master Protocol: To evaluate translational outcomes (Baseline SARS-COV-2) [ Time Frame: From randomisation to day 29 ]
    Change in viral load over time

  20. CST-2 Additional: Pharmacokinetic Objective: To define PK of EIDD-2801 and EIDD-1931 in plasma following multiple doses administered to patients with COVID-19. [ Time Frame: Samples collected on Day 1 and Day 5 post-randomisation ]
    Concentrations of EIDD-2801 and -1931 in plasma

  21. CST-2 Additional: Virologic Objective: To assess the difference in viral clearance (time to negative PCR) between EIDD-2801 and control. [ Time Frame: Swabs taken on Day 1 (day of randomisation), 3, 5, 8, 11, 15, 22 and 29 ]
    Qualitative (and quantitative when possible) PCR for SARS-CoV-2 by nasal swab.

  22. CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (FLU-PRO) [ Time Frame: From randomisation to Day 29 ]
    Patient Reported Outcome Measures (FLU-PRO).

  23. CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (WHO Scale). [ Time Frame: From randomisation to Day 29 ]
    WHO Progression Scale at day 15 and 29

  24. CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (NEWS2) [ Time Frame: From randomisation to Day 29 ]
    NEWS2 (National Early Warning Score2) assessed during study clinic visit on days 15 and 29.

  25. CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (mortality) [ Time Frame: From randomisation to Day 29 ]
    Mortality at Days 15 and 29

  26. CST-2 Additional: Clinical Objective: To determine the ability of EIDD-2801 to reduce the duration of signs and symptoms of COVID-19 in patients (death) [ Time Frame: From randomisation to Day 29 ]
    Time from randomisation to death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Master Protocol Inclusion Criteria:

  1. Adults (≥18 years) with laboratory-confirmed* SARS-CoV-2 infection (PCR)
  2. Ability to provide informed consent signed by study patient or legally acceptable representative
  3. Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in the protocol) from the first administration of trial treatment, throughout trial treatment and for the duration outlined in the candidate-specific trial protocol after the last dose of trial treatment

    • If any CSTs are included in the community setting, the CST protocol will clarify whether patients with suspected SARS-CoV-2 infection are also eligible.

Standard additional criteria that may be applied per CST protocol:

Group A (severe disease) 4a. Patients with clinical status of Grades 4 (hospitalised, oxygen by mask or nasal prongs), 5 (hospitalised, on non-invasive ventilation, or high flow oxygen), 6 (hospitalised, intubation and mechanical ventilation) or 7 (ventilation and additional organ support - pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO)), as defined by the WHO clinical severity score, 9-point ordinal scale.

Group B (mild-moderate disease) 4b. Ambulant or hospitalised patients with the following characteristics peripheral capillary oxygen saturation (SpO2) >94% RA N.B. The CST protocol inclusion criteria will take precedence over the master protocol inclusion criteria.

CST-2 Inclusion Criteria:

For the purpose of the EIDD-2801 candidate-specific trial the following inclusion criteria have been amended from the Master protocol to:

1. Male or female ≥ 60 years old or ≥50 years old with at least one well controlled comorbidity: cardiovascular disease, chronic lung disease (e.g. COPD, or pulmonary hypertension), immune deficiency (taking the equivalent of 20 mg prednisone daily, chemotherapy, or immune modulating biologic therapies), diabetes (treated with insulin or oral medications), BMI≥30, or hypertension requiring medication with laboratory confirmed SARS-CoV-2 infection (PCR) .

3. Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use two effective methods of contraception, one of which should be highly effective (as outlined in the protocol). For women, from the first administration of trial treatment, throughout trial and up to 50 days after the last follow up visit (50 days after day 29) and for men with female partners of child bearing potential, from the first administration until 100 days after last follow up visit (100 days after day 29).

4. Group B (mild-moderate disease): Ambulant with the following characteristics peripheral capillary oxygen saturation (SpO2) >94% RA (NB this differs to the Master Protocol which also includes hospitalised patients in this group).

Additional criteria specific to this candidate are:

5. Has signs or symptoms of COVID-19 that began within 5 days of the planned first dose of study drug.

6. Is in generally good health (except for current respiratory infection) and is free of uncontrolled chronic conditions.

7. Is willing and able to comply with all study procedures and attending clinic visits through the 4th week.

8. Has someone, aged ≥ 16 living in the same household during the dosing period.

Master Protocol Exclusion Criteria:

  1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >5 times the upper limit of normal (ULN)
  2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated glomerular filtration rate <30 mL/min/1.73 m^2)
  3. Pregnant or breast feeding
  4. Anticipated transfer to another hospital which is not a study site within 72 hours
  5. Allergy to any study medication
  6. Patients taking other prohibited drugs (as outline in CST protocol) within 30 days or 5 times the half-life (whichever is longer) of enrolment
  7. Patients participating in another CTIMP trial

    N.B. The CST protocol exclusion criteria will take precedence over the master protocol exclusion criteria.

    CST-2 Exclusion Criteria:

    Additional criteria specific to this candidate are:

  8. Has a febrile respiratory illness that includes signs of pneumonia, or requires hospitalization, oxygenation, mechanical ventilation, or other supportive modalities.
  9. Has a platelet count less than 50x10^9/L, or lymphocytes less than 0.2x10^9/L, haemoglobin less than 10 g/dL, or has a disorder of the hematologic system including anaemic disorder or other blood dyscrasia, cancer of the hematologic system, history of bone marrow transplant, or other significant hematologic disease at screening.
  10. Is experiencing adverse events or laboratory abnormalities that are Grade 3 or above based on the CTCAE scale.
  11. Has clinically significant liver dysfunction or renal impairment.
  12. Has history of Hepatitis C infection or concurrent bacterial pneumonia.
  13. Has received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 30 days prior to the first dose of study drug.
  14. In the opinion of the investigator, has significant end-organ disease as a result of relevant comorbidities: chronic kidney disease, congestive heart failure, peripheral vascular disease including diabetic ulcers.
  15. Has a SaO2<95% by oximetry or has lung disease that requires supplemental oxygen.
  16. Has any condition that would, in the opinion of the investigator, put the patient at increased risk for participation in a clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04746183


Contacts
Layout table for location contacts
Contact: Helen E Reynolds +44 (0)1517945553 livagile@liv.ac.uk

Locations
Layout table for location information
South Africa
Desmond Tutu Health Foundation Not yet recruiting
Cape Town, South Africa
Contact: Alicia James         
Principal Investigator: Catherine Orrell         
Ezintsha Not yet recruiting
Johannesburg, South Africa
Contact: Francois Venter         
Principal Investigator: Nomathemba Chandiwana         
United Kingdom
Liverpool University Hospitals NHS Foundation Trust Recruiting
Liverpool, United Kingdom, L7 8XP
Contact    +44 (0)151 706 4863    agile.accord@nhs.net   
Contact    +44(0)7342065915      
Principal Investigator: Richard FitzGerald         
Principal Investigator: Lauren Walker         
Kings College Hospital NHS Foundation Trust Not yet recruiting
London, United Kingdom
Manchester University NHS Foundation Trust Recruiting
Manchester, United Kingdom
Principal Investigator: Shazaad Ahmad         
University Hospital Southampton NHS Foundation Trust Recruiting
Southampton, United Kingdom, SO16 6YD
Contact    +44 (0)7469565895    UHS.SouthamptonCRF@nhs.net   
Principal Investigator: Chris Edwards         
Sponsors and Collaborators
University of Liverpool
University of Southampton
Liverpool School of Tropical Medicine
Liverpool University Hospitals NHS Foundation Trust
University of Cambridge
Investigators
Layout table for investigator information
Principal Investigator: Saye Khoo University of Liverpool
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Liverpool
ClinicalTrials.gov Identifier: NCT04746183    
Other Study ID Numbers: UoL001542
First Posted: February 9, 2021    Key Record Dates
Last Update Posted: August 25, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Master protocol publication. Data sets will be registered on CSDR
Supporting Materials: Study Protocol
Time Frame: Master protocol published 19 June 2020
Access Criteria: Master protocol available from https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04473-1

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Liverpool:
SARS coronavirus 2
SARS-CoV-2
Phase I
Phase II
Platform trial
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Nitazoxanide
Antiparasitic Agents
Anti-Infective Agents